Navigation Links
Anti-sense might make sense for treating liver cancer
Date:1/3/2012

COLUMBUS, Ohio A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer. The findings might offer a new therapy for this malignancy, which kills an estimated 549,000 people worldwide annually.

The animal study, by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at Mayo Clinic, focused on microRNA-221 (miR-221), a molecule that is consistently present at abnormally high levels in liver cancer.

To control the problem molecule, the researchers designed a second molecule as a kind of mirror image of the first. That mirror molecule is called an antisense oligonucleotide, and it selectively bound to and blocked the action of miR-221 in human liver cancer transplanted into mice. The treatment significantly prolonged the animals' lives and promoted the activity of important tumor-suppressor genes.

"This study is significant because hepatocellular carcinoma, or liver cancer, generally has a poor prognosis, so we badly need new treatment strategies," says principal investigator Thomas Schmittgen, associate professor and chair of pharmaceutics at Ohio State's College of Pharmacy and a member of the OSUCCC James Experimental Therapeutics program.

The findings are published in the journal Cancer Research.

For the study, Schmittgen and his colleagues injected liver cancer cells labeled with the luminescent lighting-bug protein luciferase into the livers of mice. The researchers used bioluminescence imaging to monitor tumor growth.

When the tumors reached the appropriate size, they gave one group of animals the molecule designed to block miR-221; the other group received a control molecule.

Key findings include the following:

  • After treatment with the antisense oligonucleotide, half the treated animals were alive at 10 weeks versus none of the controls.

  • The antisense oligonucleotide significantly reduced levels of miR-221 in both tumor and normal liver samples.

  • Treatment with the antisense oligonucleotide caused a three-fold increase in the activity of three important tumor-suppressor genes that are blocked by miR-221 in liver cancer. (The tumor suppressors were p27, p57 and PTEN.)

"Overall, this study provides proof-of-principle for further development of microRNA-targeted therapies for hepatocellular carcinomas," Schmittgen says.


'/>"/>
Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Herpes Drug Might Also Slow HIV Progression
2. Bonding Hormone Might Help Some With Autism
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Bilingualism Might Begin in the Womb
5. Teens Might Exercise More If They Think Its Fun
6. Gas Cooking Might Up Your Cancer Risk
7. Afternoon Nap Might Make You Smarter
8. What it might take to unravel the lean mean machine that is cancer
9. Increasing neurogenesis might prevent drug addiction and relapse
10. Kids Peanut Allergies Might Be Tamed: Study
11. Blood Test Might Sort Out Milk Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... a neurosurgeon, has received a big bump in sales after recently going ... currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, RevNutrition.com and Go4ItNutrition.com. ...
(Date:9/19/2017)... Glen Cove, New York (PRWEB) , ... September 19, 2017 , ... ... that its dentist, Dr. Andrew Sami, was recently named one of the best dentists ... the leading lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... update their mobile app offering. The new app provides a modern design with ... the overall shopping experience. , The fred’s Pharmacy mobile app includes hundreds of ...
(Date:9/18/2017)... ... September 19, 2017 , ... Food ... market , expected to grow at the fastest CAGR of 9.1% over the ... Food Protein Trends & Growth Opportunities in Asia’ – highlighting alternative proteins, sustainable ...
(Date:9/18/2017)... ... September 18, 2017 , ... Allegheny Health Network’s (AHN) string of standout ... fifth consecutive year, AHN earned more honors than any health care provider in the ... dinner Sept. 14 at the Omni William Penn Hotel in downtown Pittsburgh included:, ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology: